Memantine And Donepezil Hydrochlorides Extended-release Capsule, Extended Release
Product Images NDC 73190-004

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Memantine And Donepezil Hydrochlorides Extended-release (NDC 73190-004). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avkare, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

30 (004 30)

The label for Memantine and Donepezil Hydrochlorides Extended-release Capsules by AvKARE shows the combined strengths of 28 mg Memantine and 10 mg Donepezil per capsule. It indicates 30 capsules in the package as prescription-only (Rx Only). Storage and dosage instructions, manufacturer details, and barcodes are also visible.*

FDA Label Image

Chem Structure 1 (Memantine And Donepezil Hydrochlorides Extended Re 1)

Chemical structure diagram of Memantine Hydrochloride, showing a tricyclic amine structure with amino and methyl substituents.*

FDA Label Image

Figure 8 (Memantine And Donepezil Hydrochlorides Extended Re 10)

A line graph comparing the cumulative percentage of patients versus ADCS-ADL change from baseline, showing two groups: donepezil hydrochloride 10 mg/day and placebo. The x-axis represents the ADCS-ADL change from baseline, ranging from -20 to 20, and the y-axis shows cumulative percentage of patients from 0% to 100%. Donepezil data points are marked with filled circles and placebo with open squares.*

FDA Label Image

Chem Structure 2 (Memantine And Donepezil Hydrochlorides Extended Re 2)

Chemical structure of Donepezil Hydrochloride, showing its molecular arrangement including aromatic rings, methoxy groups, a carbonyl group, and a piperidine ring bound to a benzyl moiety hydrochloride salt.*

FDA Label Image

Figure 1 (Memantine And Donepezil Hydrochlorides Extended Re 3)

A line graph depicting mean change from baseline in SIB score over 24 weeks of treatment. The x-axis represents weeks of treatment (0 to 24), and the y-axis shows mean change in SIB score ranging from -2 to 5. Two lines compare Memantine HCl ER 28 mg/AChEI and Placebo/AChEI groups, with clinical improvement and decline indicated. Error bars show variability for each data point.*

FDA Label Image

Figure 2 (Memantine And Donepezil Hydrochlorides Extended Re 4)

A cumulative percentage curve showing SIB (Severe Impairment Battery) change from baseline in patients. The graph compares Memantine HCl ER 28 mg/AChe and Placebo/AChe groups across a range of SIB changes, with cumulative percentage of patients on the vertical axis and SIB change on the horizontal axis.*

FDA Label Image

Figure 3 (Memantine And Donepezil Hydrochlorides Extended Re 5)

A line graph showing the mean Clinical Dementia Rating-Sum of Boxes (CDR-SB) scores over 24 weeks of treatment. The x-axis represents weeks of treatment from 0 to 24, and the y-axis shows the mean score values. Two lines compare Memantine HCl ER 28 mg/AChEI and Placebo/AChEI, with annotations indicating clinical improvement and clinical decline trends.*

FDA Label Image

Figure 4 (Memantine And Donepezil Hydrochlorides Extended Re 6)

A bar chart comparing patient percentages across CIBIC-Plus rating categories for Memantine HCl ER 28 mg/AChE (black bars) versus Placebo/AChE (white bars). Categories range from Marked Improvement to Marked Worsening, with the highest percentage of patients showing No Change in both groups.*

FDA Label Image

Figure 5 (Memantine And Donepezil Hydrochlorides Extended Re 7)

A line graph depicting the change from baseline in SIB (Severe Impairment Battery) scores over six months of drug treatment. The graph compares donepezil hydrochloride 10 mg/day (solid line with filled circles) showing clinical improvement, and placebo (dashed line with open squares) showing clinical decline. The y-axis represents the mean change from baseline with standard error bars, and the x-axis represents months of drug treatment (0, 3, and 6 months). Annotations indicate clinical improvement above baseline and clinical decline below baseline.*

FDA Label Image

Figure 6 (Memantine And Donepezil Hydrochlorides Extended Re 8)

A line graph showing the cumulative percentage of patients versus SIB (Severe Impairment Battery) change from baseline. The graph compares donepezil hydrochloride 10 mg/day with placebo, indicating a higher cumulative percentage of patients achieving better SIB change with donepezil over time.*

FDA Label Image

Figure 7 (Memantine And Donepezil Hydrochlorides Extended Re 9)

A line graph comparing the change from baseline over six months in ADCS-ADL scores between donepezil hydrochloride 10 mg/day and placebo. The y-axis shows mean change with standard error, where positive values indicate clinical improvement and negative values clinical decline. The donepezil group shows less decline than placebo over time.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.